Current Hematologic Malignancy Reports

Papers
(The H4-Index of Current Hematologic Malignancy Reports is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas50
MLL-Rearranged Acute Lymphoblastic Leukemia47
IDH Inhibitors in AML—Promise and Pitfalls32
Extramedullary Disease in Multiple Myeloma32
MRD Assessment in Multiple Myeloma: Progress and Challenges27
Artificial Intelligence in Hematology: Current Challenges and Opportunities27
Management of Ibrutinib Toxicities: a Practical Guide24
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib20
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments20
Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults18
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia17
Treatment-Free Remission: the New Goal in CML Therapy16
Enteropathy-Associated T cell Lymphoma16
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review15
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms14
Thrombocytosis and Thrombosis: Is There Really a Correlation?14
0.020988941192627